NDAINTRAVENOUSEMULSION
Approved
Oct 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VARUBI (rolapitant hydrochloride) is a neurokinin-1 (NK1) receptor antagonist administered intravenously as an emulsion for the prevention of chemotherapy-induced nausea and vomiting (CINV). It works by blocking substance P signaling in the chemoreceptor trigger zone and vomiting center. The drug is indicated for use alongside 5-HT3 antagonists and corticosteroids in patients receiving highly emetogenic chemotherapy.
Peak6.1 years to LOE
Product is in peak commercial phase post-approval; team size and investment level likely stable but subject to competitive pressures in the antiemetic space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VARUBI offers solid exposure to commercial execution in an established oncology supportive care market, with emphasis on payer relationships and field presence rather than clinical development. The lack of current clinical pipeline activity means career progression will depend on commercial achievement and cross-functional initiatives rather than novel trial launches.
Brand Manager
Worked on VARUBI at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.